[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL271430A - Methods to treat opioid use disorder - Google Patents

Methods to treat opioid use disorder

Info

Publication number
IL271430A
IL271430A IL271430A IL27143019A IL271430A IL 271430 A IL271430 A IL 271430A IL 271430 A IL271430 A IL 271430A IL 27143019 A IL27143019 A IL 27143019A IL 271430 A IL271430 A IL 271430A
Authority
IL
Israel
Prior art keywords
methods
use disorder
opioid use
treat opioid
treat
Prior art date
Application number
IL271430A
Other languages
Hebrew (he)
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of IL271430A publication Critical patent/IL271430A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL271430A 2017-06-16 2019-12-15 Methods to treat opioid use disorder IL271430A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762521121P 2017-06-16 2017-06-16
US201762572331P 2017-10-13 2017-10-13
US201762572996P 2017-10-16 2017-10-16
US201762598338P 2017-12-13 2017-12-13
US201862632995P 2018-02-20 2018-02-20
US201862656216P 2018-04-11 2018-04-11
US201862680935P 2018-06-05 2018-06-05
PCT/IB2018/000770 WO2018229551A2 (en) 2017-06-16 2018-06-15 Methods to treat opioid use disorder

Publications (1)

Publication Number Publication Date
IL271430A true IL271430A (en) 2020-01-30

Family

ID=63407480

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271430A IL271430A (en) 2017-06-16 2019-12-15 Methods to treat opioid use disorder

Country Status (5)

Country Link
EP (1) EP3638240A2 (en)
AU (1) AU2018283724B2 (en)
IL (1) IL271430A (en)
NZ (1) NZ760033A (en)
WO (1) WO2018229551A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249274B2 (en) 2004-06-04 2011-02-24 Camurus Ab Liquid depot formulations
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2016071767A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
AU2016349111A1 (en) 2015-11-04 2018-05-17 Indivior Uk Limited Quantification of drugs in biological samples

Also Published As

Publication number Publication date
WO2018229551A2 (en) 2018-12-20
EP3638240A2 (en) 2020-04-22
WO2018229551A3 (en) 2019-02-14
AU2018283724A1 (en) 2020-01-16
NZ760033A (en) 2023-02-24
AU2018283724B2 (en) 2021-08-19
AU2018283724A2 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods of treating fgf21-associated disorders
ZA201705673B (en) Methods for treating skin
IL258931A (en) Therapeutic compounds and methods
HK1259336A1 (en) Methods for treating myeloproliferative disorders
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
IL250677A0 (en) Treatment of cancers using anti-nkg2a agents
GB201701673D0 (en) Methods of well treatment
HK1256036A1 (en) Methods for treating myeloproliferative disorders
AU362358S (en) Pet treat
EP2970317A4 (en) Pyrimido-diazepinone compounds and methods of treating disorders
HK1244681A1 (en) Therapeutic combinations and methods for treating neoplasia
PL3215219T3 (en) Skin treatment system
IL293712A (en) Methods of treating mild brain injury
IL252296A0 (en) Methods of treating multiple sclerosis
HK1220209A1 (en) Methods of treating acute kidney injury
HK1215164A1 (en) Treatment methods
HK1259445A1 (en) Combinations to treat cancer
GB201416832D0 (en) Methods of treatment
IL250658A0 (en) Methods of treating mild brain injury
HK1249866A1 (en) Methods of treatment with taselisib
IL271430A (en) Methods to treat opioid use disorder
SG11201700059WA (en) Therapeutic agent for keratoconjunctive disorder
GB201400311D0 (en) Treating Susceptibility
GB201512139D0 (en) Methods of treatment
GB201608599D0 (en) Treatment of opioid tollerence